TriVascular Overview
- Founded
-
1998

- Status
-
Acquired/Merged
- Employees
-
202

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$107M
TriVascular General Information
Description
Developer of endovascular aortic repair (EVAR) stent graft systems. The company provides product for treatment of abdominal aortic aneurysms and also provides thoracic stent graft systems for the treatment of the thoracic aorta.
Contact Information
Formerly Known As
TV2 Holding
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Diagnostic Equipment
Therapeutic Devices
Parent Company
Primary Office
- 3910 Brickway Boulevard
- Santa Rosa, CA 95403
- United States
+1 (707) 000-0000
TriVascular Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
25. Merger/Acquisition | 03-Feb-2016 | $107M | 000.00 | 00000 | Completed | Profitable |
24. Debt - General | 20-Aug-2015 | 0000 | 000.00 | Completed | Profitable | |
23. IPO | 16-Apr-2014 | 0000 | 000.00 | 00000 | Completed | Generating Revenue/Not Profitable |
22. Restart - Later VC | 12-Dec-2013 | 00.000 | 00.000 | Completed | Profitable | |
21. Restart - Later VC (Series E) | 07-Nov-2013 | 000.00 | 000.00 | Completed | Profitable | |
20. Debt - General | 05-Feb-2013 | 000.00 | Completed | Profitable | ||
19. Debt - General | 31-Oct-2012 | 0000 | 000.00 | Completed | Profitable | |
18. Restart - Later VC (Series D) | 24-Oct-2012 | 000.00 | 000.00 | Completed | Profitable | |
17. Restart - Later VC | 25-May-2012 | $4M | $4M | Completed | Product Development | |
16. Restart - Later VC | 22-Feb-2012 | $7.2M | $7.2M | Completed | Product Development |
TriVascular Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of endovascular aortic repair (EVAR) stent graft systems. The company provides product for treatment of abdomi
Surgical Devices
Santa Rosa, CA
202
As of 2015
000.00
0000
0000-00-00
000000&0
000.00
TriVascular Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Endologix | Corporation | Irvine, CA | 000 | 0000 | 0000000000. | |
0000000000000 | Corporation | New York, NY | 000 | 000.00 | 000000 - 000 | 000.00 |
TriVascular Patents
TriVascular Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2018517464-A | Stent-graft with improved flexibility | Granted | 11-May-2015 | 00000000 | |
JP-6857140-B2 | Stent-graft with increased flexibility | Active | 11-May-2015 | 00000000 | |
JP-2021098146-A | Stent-graft with improved flexibility | Pending | 11-May-2015 | 00000000 | |
US-20180110609-A1 | Stent-graft with improved flexibility | Pending | 11-May-2015 | 00000000 | 0 |
EP-3294210-A1 | Stent-graft with improved flexibility | Pending | 11-May-2015 | A61F2/07 |
TriVascular Executive Team (20)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Michael Kramer | Chief Financial Officer |
TriVascular Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Daniel Moore | Self | Board Member | 000 0000 |
Jake Nunn | New Enterprise Associates | Board Member | 000 0000 |
TriVascular Signals
TriVascular Former Investors (17)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
ABS Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Boston Scientific Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
De Novo Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 |